NEW YORK (GenomeWeb News) — Compugen and the Mayo Clinic plan to discover and validate biomarkers that could detect plaques linked to heart and brain diseases, the company said today.
 
Under the agreement, Compugen will retain exclusive commercialization rights to any products that result from the collaboration, which aims to find biomarkers for atherosclerotic plaques in coronary artery disease and in cerebrovascular disease.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.